WASHINGTON — President Trump will nominate Dr. Scott Gottlieb, a longtime drug industry financier and advocate for deregulation, to run the Food and Drug Administration, the White House said Friday.

Gottlieb, 44, is a physician and resident fellow at the conservative American Enterprise Institute. He trained at Mount Sinai School of Medicine, then pursued an unusual career that has taken him from hospitals to Wall Street to the FDA and back to Wall Street. A prolific writer and speaker on medical innovation, Gottlieb served as an FDA deputy commissioner under George W. Bush and has frequently testified before Congress.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • He’s baaaack. Most notably cited in
    “How Many More Mike Browns Are Out There?”, Time Magazine; 9/25/2005.
    http://content.time.com/time/magazine/article/0,9171,1109345,00.html.

    Gottlieb oversaw the plummet in inspections and compliance actions and the resulting alarming spike in tainted drugs, adverse events that soon followed. I remember those days. Very Anti-Whistleblower also. Did Trump supporters really vote for being poisoned again?
    He should just stay in WallStreet where his garbage belongs.

  • What are the politics, of Dr.gottliebs on the so-called opioid crisis?. Will he be compassionate, with the true pain sufferers, that take pain meds, in a responsible way?, or will he be, putting,them with the good,bad and the ugly. Meaning those that abuse,sell, and those,who really need for pain, but are in fear, of being rounded, up with, the so-called opioid crisis. As is, now opioid , meds are being ,cut in production, of 25% .also doctors are being, advice to give less, or cut the pain meds from their patients,due to being put on the, bad list.. very sad
    Wake up America!!!.

  • When a whistle-blower went to the FDA in 2011 and said NECC would harm or kill patients the FDA did nothing. In 2012 76 patients died because of NECC let’s hope this guy listenesaid to whistleblowers.

Your daily dose of news in health and medicine

Privacy Policy